<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05015972</url>
  </required_header>
  <id_info>
    <org_study_id>CTA30X</org_study_id>
    <nct_id>NCT05015972</nct_id>
  </id_info>
  <brief_title>UCAR-T for CD19+ Refractory/Relapsed B Hematologic Malignancies</brief_title>
  <official_title>A Study of CTA30X UCAR-T Cell Injection in the Treatment of Patients With r/r CD19+ B Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>920th Hospital of Joint Logistics Support Force of People's Liberation Army of China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nanjing Bioheng Biotech Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>920th Hospital of Joint Logistics Support Force of People's Liberation Army of China</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single arm, open-label, single-center prospective study to determinethe safety and&#xD;
      efficacy of CTA30X UCAR-T cells in patients diagnosed with CD19+ refractory/relapsed B&#xD;
      Hematologic Malignancies&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main aim of the study is to determine the safety and efficacy of CTA30X UCAR-T in R/R B&#xD;
      Hematologic Malignancies. CTA30X UCAR-T is an allogeneic chimeric antigenreceptor T-cell&#xD;
      (CAR-T) therapy that targets CD19 and B-cell Hematologic Malignancies. The study will include&#xD;
      72 subjects to receive CTA30X UCAR-T singleinfusion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">August 20, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limiting toxicity</measure>
    <time_frame>Up to 24 weeks after CAR-T infusion</time_frame>
    <description>CRS lasting ≥7 days G3 or ≥G4 after CTA30X infusion;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of AE after CAR-T infusion</measure>
    <time_frame>Up to 4 weeks after the infusion of CAR-T cells</time_frame>
    <description>Incidence of adverse events after CTA30X UCAR-T infusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR rate</measure>
    <time_frame>1month, 3months after CTA30X UCAR-T infusion</time_frame>
    <description>Overall response rate (ORR=CR+CRi) after CTA30X UCAR-T infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRD-ORR</measure>
    <time_frame>within 3months after CTA30X UCAR-T infusion</time_frame>
    <description>The overall response rate was MRD negative within 3 months after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BOR</measure>
    <time_frame>within 3months after CTA30X UCAR-T infusion</time_frame>
    <description>The best overall response within 3 months after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOR</measure>
    <time_frame>From the onset of a tumor from the first assessment of CR or PR up to 1 year</time_frame>
    <description>Duration of remission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>6month, 12months、 18months and24months after CTA30X UCAR-T infusion</time_frame>
    <description>ORR=CR+CRi</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EFS</measure>
    <time_frame>6month, 12months、 18months and24months after CTA30X UCAR-T infusion</time_frame>
    <description>Event-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>6month, 12months、 18months and24months after CTA30X UCAR-T infusion</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <other_outcome>
    <measure>exploratory</measure>
    <time_frame>up to 24 months after CAR-T infusion</time_frame>
    <description>The proliferation and survival time of CAR T cells in vivo and the clearance rate of B cells.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>B-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>CTA30X UCAR-T treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CD19+ R/R B Hematologic Malignancies patients be treated with a single dose of CTA30X UCAR-T cells. Total dose of(5-30)*10E6/kg cells will be administered at Day 0</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CTA30X UCAR-T injection</intervention_name>
    <description>CTA30X UCAR-T injection is an allogeneic CAR-Ttargeted CD19 . A single infusion of CART cells will be administered intravenously.</description>
    <arm_group_label>CTA30X UCAR-T treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Inclusion criteria applicable only to ALL:&#xD;
&#xD;
          1. Age ≥3 and &lt; 70 years old, gender is not limited;&#xD;
&#xD;
          2. Patients with a histologic diagnosis of CD19+ B-ALL according to the National&#xD;
             Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Acute&#xD;
             Lymphoblastic Leukemia (2016.v1);&#xD;
&#xD;
          3. Meet the R/R CD19+ B-ALL diagnosis, including any of the following conditions:&#xD;
&#xD;
             A) No CR after standard chemotherapy; B) CR was induced for the first time, but the&#xD;
             duration of CR was less than 12 months; C) R/R CD19+ B-ALL that failed after the first&#xD;
             or repeated remedial therapy; D) 2 or more recurrences;&#xD;
&#xD;
          4. Number of primary cells (primary + juvenile) in bone marrow, &gt; 5% (morphology) and/or&#xD;
             &gt; 1% (flow cytometry);&#xD;
&#xD;
          5. Philadelphia chromosomal negative (PH -) subjects;Philadelphia chromosomal positive&#xD;
             (pH +) subjects who either cannot tolerate or do not respond to either of the TKI&#xD;
             treatments;&#xD;
&#xD;
        Inclusion criteria for NHL only:&#xD;
&#xD;
          1. Age ≥18 years old and &lt; 70 years old, regardless of gender;&#xD;
&#xD;
          2. According to the 2016 WHO classification criteria for lymphocytic tumors, the&#xD;
             histological diagnosis included: DLBCL (NOS);Subjects with follicular lymphoma,&#xD;
             chronic lymphocytic leukemia/small lymphocytic lymphoma transformation, and PMBCL and&#xD;
             high-grade B-cell lymphoma;&#xD;
&#xD;
          3. Relapsed or refractory B-NHL (meets one of the following conditions) :&#xD;
&#xD;
             A) Subjects have no remission or recurrence after receiving second-line chemotherapy&#xD;
             regimen or above; B) primary drug resistance; C) Subjects relapse after autologous&#xD;
             hematopoietic stem cell transplantation;&#xD;
&#xD;
          4. According to Lugano 2014 criteria, there should be at least one evaluable tumor focus;&#xD;
&#xD;
        Common standards for ALL and NHL:&#xD;
&#xD;
          1. Serum total bilirubin ≤51 umol/L, serum ALT and AST ≤ 3 times of the upper limit of&#xD;
             the normal range, serum creatinine ≤176.8 umol /L;&#xD;
&#xD;
          2. Echocardiography showed left ventricular ejection fraction (LVEF) ≥50%;&#xD;
&#xD;
          3. Subjects have no active pulmonary infection, and oxygen saturation of suction finger&#xD;
             vein is ≥92%;&#xD;
&#xD;
          4. The estimated survival time is more than 3 months;&#xD;
&#xD;
          5. ECOG score 0-2;&#xD;
&#xD;
          6. Subjects or their legal guardians participate in this study voluntarily and sign the&#xD;
             informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Extramedullary lesions, except those with effectively controlled CNSL (CNS-1);(All&#xD;
             patients only)&#xD;
&#xD;
          2. A lymphoblastic crisis of chronic myeloid leukemia, Burkitt's leukemia/lymphoma, was&#xD;
             diagnosed according to WHO classification;(All patients only)&#xD;
&#xD;
          3. having a genetic syndrome such as Fanconi anemia, Kostmann syndrome, Shwachman&#xD;
             syndrome or any other known bone marrow failure syndrome;(All patients only)&#xD;
&#xD;
          4. Extranodal intracranial lesions (tumor cells in CSF and/or intracranial lymphoma shown&#xD;
             on MRI);(For patients with NHL only)&#xD;
&#xD;
          5. subjects with extensive gastrointestinal lymphoma invasion;(For patients with NHL&#xD;
             only)&#xD;
&#xD;
          6. Subjects received radiotherapy, chemotherapy and monoclonal antibody treatment within&#xD;
             1 week before screening;&#xD;
&#xD;
          7. Have a history of allergy to any one ingredient in cell products;&#xD;
&#xD;
          8. Prior use of any CAR T cell product or other genetically modified T cell therapy&#xD;
&#xD;
          9. Subjects with cardiac dysfunction grade III or IV according to the New York Heart&#xD;
             Association (NYHA) cardiac function classification standards;&#xD;
&#xD;
         10. Myocardial infarction, cardiac angioplasty or stenting, unstable angina pectoris or&#xD;
             other clinically serious heart disease within 12 months of enrollment;&#xD;
&#xD;
         11. Severe primary or secondary hypertension of grade 3 or higher (WHO Hypertension&#xD;
             Guidelines, 1999);&#xD;
&#xD;
         12. Patients with prolonged QT interval indicated by ECG and previous severe heart disease&#xD;
             such as severe arrhythmia;&#xD;
&#xD;
         13. Previous history of craniocerebral trauma, disturbance of consciousness, epilepsy,&#xD;
             cerebrovascular ischemia, cerebrovascular hemorrhagic disease, etc.&#xD;
&#xD;
         14. Severe active infection (except simple urinary tract infection and bacterial&#xD;
             pharyngitis);&#xD;
&#xD;
         15. Subject has a history of other primary cancers except for:&#xD;
&#xD;
             A. Non-melanoma cured by excision, such as basal cell carcinoma of the skin; B.&#xD;
             Cervical carcinoma in situ, local prostate cancer, and ductal carcinoma in situ with&#xD;
             disease-free survival ≥2 years after adequate treatment;&#xD;
&#xD;
         16. Subjects with autoimmune diseases requiring treatment or subjects requiring&#xD;
             immunosuppressive therapy;&#xD;
&#xD;
         17. Patients with graft-versus-host disease (GVHD) and/or requiring immunosuppressive&#xD;
             therapy;&#xD;
&#xD;
         18. Live vaccine inoculation within 4 weeks before screening;&#xD;
&#xD;
         19. Subjects have a history of alcohol, drug abuse or mental illness;&#xD;
&#xD;
         20. During screening, if the subjects were HBV surface antigen positive, they were tested&#xD;
             by active hepatitis B PCR. If HBV DNA copy number &gt; 1000, they were excluded; if HBV&#xD;
             DNA copy number ≤1000, routine antiviral treatment was required after&#xD;
             enlistment).Hepatitis C, syphilis antibody positive, syphilis virus DNA test exceeded&#xD;
             the upper limit of normal value and CMV virus DNA test exceeded the upper limit of&#xD;
             normal value;&#xD;
&#xD;
         21. Subjects who were receiving systemic steroid therapy prior to screening and were&#xD;
             determined by the investigator to require long-term systemic steroid therapy during&#xD;
             the treatment period (other than inhalation or topical use);&#xD;
&#xD;
         22. Screening participants who had participated in other clinical trials within the&#xD;
             previous 2 weeks;&#xD;
&#xD;
         23. Pregnant and lactating women and fertile subjects who are unable to take effective&#xD;
             contraceptive measures (both male and female);&#xD;
&#xD;
         24. Any situation that the investigator believes may increase the risk to the subject or&#xD;
             interfere with the outcome of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wang Sanbin, Doctor</last_name>
    <phone>(+86)13187424131</phone>
    <email>Sanbin1011@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Li Shiqi, Doctor</last_name>
    <phone>(+86)15398671578</phone>
    <email>Lystch@outlook.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>No.212 Daguan Road, Xishan District</name>
      <address>
        <city>Kunming</city>
        <state>Yunnan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 21, 2021</study_first_submitted>
  <study_first_submitted_qc>August 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 23, 2021</study_first_posted>
  <last_update_submitted>August 15, 2021</last_update_submitted>
  <last_update_submitted_qc>August 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>UCAR-T</keyword>
  <keyword>allogeneic</keyword>
  <keyword>CD19</keyword>
  <keyword>B-ALL</keyword>
  <keyword>B-NHL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

